Contagion Live: Targeting Lung Blood Vessel Inflammation in COVID-19 Patients
UC cardiologist discusses use of razuprotafib to lessen blood vessel inflammation
Richard Becker, MD, director of the UC Heart, Lung and Vascular Institute, was interviewed by a reporter for Contagion Live about a new phase 2 clinical trial UC and UC Health are conducting using the drug razuprotafib, to lessen inflammation of the blood vessels in COVID-19 patients. Razuprotafib activates a key pathway for stabilizing blood vessels in the lungs and may prevent or treat respiratory distress in COVID-19 patients. Becker, also a UC Health cardiologist, and Duncan Hite, a professor in the UC College of Medicine, and medical director of critical care at UC Health, are overseeing the trial using razuprotafib at UC. The drug is being used as a part of clinical trial in 20 sites across the nation.
Listen to the Contagion Live interview online.
Learn more about the research involving Dr. Becker and Dr. Hite.
Related Stories
Nurses are in high demand
March 3, 2026
WCPO recently spoke with faculty and students at UC College of Nursing about the education pipeline needed to train more nurses to meet a growing demand for healthcare nationally.
UC’s ‘Healthcare Heroes’ change lives in and beyond Cincinnati
March 3, 2026
The Cincinnati Business Courier released its list of "2026 Healthcare Heroes," with one-third of the list made up of UC-affiliated entrepreneurs and medical professionals.
German TV highlights UC expert's ancient Maya discoveries
March 2, 2026
The German television show 'Unsolved Case' talks to a University of Cincinnati expert about ballcourts used by the ancient Maya for a program examining how people used spheres as both tools and toys.